drugset / Trial / NCT00429533

Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris

NCT00429533

Phase 2 Terminated 48 enrolled Jacobus Pharmaceutical
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this 12-month study was to determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance phase pemphigus vulgaris.

Timeline

Start
1996-11
Primary completion
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapsone Small molecule 150 mg
Subject Dapsone Small molecule 200 mg

Indications